This solution involves the development of phytomedicines derived from Viola herb actives to manage periodontal disease. The project focuses on isolating bioactive compounds, understanding their antimicrobial and anti-inflammatory properties, and creating a standardized herbal preparation for oral care products.
Violacean phytomedicines represent a novel approach to managing periodontal disease through the use of bioactive compounds found in Viola herbs. These compounds exhibit antimicrobial and anti-inflammatory properties, making them suitable for oral care applications such as toothpaste or mouthwash. The goal is to develop a standardized herbal preparation that can be commercialized as an effective oral health product.
Currently at TRL 3, the technology involves active research and development phases, with laboratory validation underway. Future work includes preclinical safety assessments and proof-of-concept studies in periodontitis models.
The University of Vienna is Austria’s largest public research university, with about 85,000 students and 11,000 staff, and a broad, internationally connected research profile. Its urban location places corporate R&D teams within Vienna’s dense academic, medical, technology and startup ecosystem. Joint platforms with the Medical University of Vienna, including the Max Perutz Labs at the Vienna BioCenter, support shared infrastructure and cross-institutional collaboration. Research services support competitive funding from the Austrian Science Fund, Austrian Research Promotion Agency, Vienna Science and Technology Fund and EU programmes. A dedicated technology-transfer function helps companies identify partners and technologies while supporting cooperation agreements, IP protection, licensing, spin-offs and startups.